NanoViricides Registers Phase II Ebola Trial for NV-387 Oral Gummies in DRC

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage developer of antiviral drugs, has announced that its Phase II clinical trial evaluating NV-387 Oral Gummies as a treatment for Bundibugyo ebolavirus and other Ebola viruses in the Democratic Republic of Congo (DRC) has been registered in the Pan African Clinical Trials Registry under identification number PACTR202608748555077. This registration is a crucial step in the fight against Ebola, as it paves the way for a much-needed oral treatment option that could be more accessible and easier to administer in outbreak settings.

The company previously received local regulatory approval from ACOREP to begin the trial, and it has confirmed that NV-387 has been delivered to the clinical trial site in Ituri province, with first patient dosing anticipated within one to two weeks, barring outbreak-related impediments. The adaptive trial will begin with a single-arm safety and dose run-in before progressing to a randomized, controlled, open-label efficacy evaluation. This design allows for flexibility and efficiency in assessing the drug's safety and effectiveness.

NV-387 is an orally administered broad-spectrum antiviral designed to mimic host-side features required by viruses for infection. Its mechanism of action is innovative, as it targets host-virus interactions rather than specific viral proteins, potentially reducing the likelihood of resistance. The drug is also being evaluated in a Phase II clinical trial for Mpox in the DRC, highlighting its versatility against multiple viral threats.

The importance of this trial cannot be overstated. Ebola outbreaks have historically been devastating, with high mortality rates and limited treatment options. Current treatments for Ebola are primarily intravenous therapies, which require specialized medical infrastructure and trained personnel. An oral treatment like NV-387 could revolutionize outbreak response by enabling simpler distribution and administration, especially in remote areas where healthcare resources are scarce.

Furthermore, the registration of this trial in the Pan African Clinical Trials Registry ensures transparency and adherence to ethical standards, which is vital for building trust among local communities and the global health community. The trial's location in the DRC, a country that has experienced multiple Ebola outbreaks, demonstrates a commitment to conducting research in the regions most affected by the disease.

NanoViricides' broader pipeline is also noteworthy. The company is developing NV-387 for other viral infections, including RSV, COVID, Long COVID, Influenza, and even Measles. Its lead drug candidate is being advanced into Phase II human clinical trials, and the company is also working on drugs against a range of other viruses, including HIV, Hepatitis C, Rabies, and Dengue fever. This broad-spectrum approach could provide a much-needed arsenal against emerging and re-emerging viral threats.

The successful progression of this trial could have significant implications for global health security. If NV-387 proves safe and effective, it could become a critical tool not only for Ebola but also for other viral outbreaks, potentially reducing the burden on healthcare systems and saving countless lives. The oral formulation is particularly promising, as it could be stockpiled and deployed rapidly in emergency situations.

However, it is important to note that drug development is a lengthy and capital-intensive process. There is no guarantee that NV-387 will ultimately receive regulatory approval. The company itself acknowledges these risks, stating that "there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development." Despite these uncertainties, the initiation of a Phase II trial in an outbreak setting is a positive step forward.

The trial's registration is a testament to the collaborative efforts between NanoViricides, local regulatory bodies, and the international health community. It underscores the importance of conducting clinical trials in the regions where diseases are most prevalent, ensuring that treatments are developed with the specific needs of affected populations in mind.

For more information, visit the company's newsroom at https://nnw.fm/NNVC.